HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies.

Abstract
Programmed cell death protein 1 (PD-1) blocking agents are novel immunotherapeutics used for treatment of advanced-stage malignancies. They have shown promise in the treatment of several malignancies, with greater efficacy and better tolerability than cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking agents. However, as with anti-CTLA-4 agents, clinically significant colitis remains an important complication. Although there is growing awareness of the histopathologic features of anti-CTLA-4 therapy, there is little information on the pathologic features of anti-PD-1 colitis. We describe here the histopathologic findings in 8 patients who developed colitis while on anti-PD-1 monotherapy. The most common pattern of injury observed (5/8 cases) was an active colitis with neutrophilic crypt microabscesses and with prominent crypt epithelial cell apoptosis and crypt atrophy/dropout. These latter features are reminiscent of other colitides with prominent apoptosis such as acute graft-versus-host disease or certain drug-induced colitides. The remainder of cases (3/8) showed a lymphocytic colitis-like pattern, characterized by increased intraepithelial lymphocytes and surface epithelial injury. Apoptosis was also often increased in these cases but crypt atrophy/dropout was not present. In patients who experienced recurrence of anti-PD-1 colitis, histologic features were similar to the initial insult but, in addition, features of chronicity developed that mimicked inflammatory bowel disease (basal lymphoplasmacytosis and crypt architectural irregularity, and Paneth cell metaplasia in 1 case). Awareness of the clinical scenario, however, should allow pathologists to suggest anti-PD-1 colitis. Interestingly, recurrent colitis was observed in patients who had been off anti-PD-1 therapy for many months. As anti-PD-1 agents are increasingly used in oncology, we present this series to increase awareness of anti-PD-1 colitis among pathologists, to facilitate its timely diagnosis and treatment.
AuthorsJonathan H Chen, Maryam K Pezhouh, Gregory Y Lauwers, Ricard Masia
JournalThe American journal of surgical pathology (Am J Surg Pathol) Vol. 41 Issue 5 Pg. 643-654 (May 2017) ISSN: 1532-0979 [Electronic] United States
PMID28296676 (Publication Type: Journal Article)
Chemical References
  • Anti-Inflammatory Agents
  • Antibodies
  • Antineoplastic Agents
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents (therapeutic use)
  • Antibodies (adverse effects)
  • Antineoplastic Agents (adverse effects)
  • Apoptosis (drug effects)
  • Atrophy
  • Biopsy
  • Colectomy
  • Colitis (chemically induced, immunology, pathology, therapy)
  • Colitis, Lymphocytic (chemically induced, immunology, pathology)
  • Colon (drug effects, immunology, pathology)
  • Colonoscopy
  • Diagnosis, Differential
  • Enterocolitis, Pseudomembranous (chemically induced, immunology, pathology)
  • Female
  • Humans
  • Immunotherapy (adverse effects)
  • Inflammatory Bowel Diseases (pathology)
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Programmed Cell Death 1 Receptor (antagonists & inhibitors, immunology)
  • Remission Induction
  • Retrospective Studies
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: